Exposure to rizatriptan during pregnancy: post-marketing experience up to 30 June 2004.
Merck & Co., Inc. evaluates outcomes of the use of rizatriptan during pregnancy through a Pregnancy Registry in the United States (US) and spontaneous reports for pregnancies reported from sources outside the US. Review of the outcomes of 25 prospective pregnancy reports in the Pregnancy Registry and reports from other sources does not suggest that treatment with rizatriptan predisposes patients to spontaneous abortions or congenital anomalies. However, the number of reports is small. Healthcare providers in the United States are encouraged to report any prenatal exposure to rizatriptan by calling the Pregnancy Registry at +1 (800) 986 8999 or visiting the Registry's website at http://www.merckpregnancyregistries.com.
Fiore
M
M
Clinical Risk Management and Safety Surveillance, Merck Research Laboratories, West Point 19486, USA. maryellen_fiore@merck.com
Shields
K E
KE
Santanello
N
N
Goldberg
M R
MR
D000014:Abnormalities, Drug-Induced / Q000453:epidemiology*; D005260:Female; D006801:Humans; D011247:Pregnancy; D011256:Pregnancy Outcome / Q000453:epidemiology*; D012042:Registries; D017366:Serotonin Receptor Agonists / Q000009:adverse effects*; D014230:Triazoles / Q000009:adverse effects*; D014363:Tryptamines
D017366:Serotonin Receptor Agonists; D014230:Triazoles; D014363:Tryptamines; C093622:rizatriptan